mercredi 2 août 2017

Onco Actu du 2 août 2017

1. Biologie

Human Genetic Variation May Complicate CRISPR [The Scientist]

2. Etiologie

Periodontal Disease is Associated with Higher Risk of Several Cancer Types [AACR]

3.1 Tabac

Protecting American Families: Comprehensive Approach to Nicotine and Tobacco [FDA]

5. Traitements

Pancreatic cancer trial: Early surgery boosts success rates [BBC News]

5.10 Traitements - Essais

Broadening Clinical Trial Participation [Cancer Research Catalyst]

After French drug trial tragedy, European Union issues new rules to protect study volunteers [Science]

5.12.1 Immunothérapies - partenariats

Looking for an oncology reboot, Sanofi, Regeneron shoot for a fast and flashy FDA OK of a promising new PD-1 [EndPoint]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval [FiercePharma]

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan [BMS]

FDA grants nivolumab accelerated approval for MSI-H or dMMR colorectal cancer [FDA]

5.2 Pharma

Acalabrutinib granted Breakthrough Therapy Designation by US FDA for the treatment of patients with mantle cell lymphoma [AstraZeneca]

US FDA accepts regulatory submission for acalabrutinib and grants Priority Review [AstraZeneca]

AstraZeneca gets breakthrough status for blood cancer drug [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

Expecting Big Pharma buyers to come running after weakened AstraZeneca? Not so fast [FiercePharma]

Despite blockbuster boasts for R&D work, pressure increases on Pfizer to do a megadeal [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

EMA encourages tailored development of medicines for older people [EMA]

United Kingdom’s withdrawal from the European Union ('Brexit') [EMA]

EMA, Let's Move to Lille [EMA in Lille]

Offers to host the European Medicines Agency (EMA) [European Council]

EU drugs agency cuts workload as prepares for Brexit disruption [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

Celgene and Agios win FDA approval for targeted AML drug Idhifa [FiercePharma]

FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation [Celgene]

Celgene, Agios win a landmark FDA OK for new AML drug Idhifa [EndPoint]

FDA approves leukemia treatment developed by Celgene, Agios [Reuters]

FDA approves new targeted treatment for relapsed or refractory acute myeloid leukemia [FDA]

5.6 ESMO

Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress [Exelixis]

6.1 Observation

Patients with Advanced Cancer who Experience Sudden Cardiac Arrest Have Significantly Lower Survival Rates Compared to Patients without Cancer [ASCO]

Exercise linked to lower mortality with early prostate cancer [Reuters]

6.10 Politiques

Brexit Health Alliance warns that UK/EU negotiations put patients at risk [Pharmafile]

6.11 Patients

Naughty Crabby [Of Tumors and M.E.N.]

6.7.1 Bioinformatique

Better drugs, faster: The potential of AI-powered humans [BBC News]

The Business of Artificial Intelligence [Harvard Business Review]